ImmusanT is a clinical development-stage biotechnology company focused on an innovative disease-modifying approach to induce immune tolerance in autoimmune diseases. Using its proprietary discovery platform for targeted immunotherapy, the Company is developing a therapy and personalized diagnostics for celiac disease and is expanding to other autoimmune diseases including Type 1 diabetes.